Busan, South Korea

Bo Suel Kim

This inventor holds 2 USPTO granted patents. Top assignee: Korean Drug Co., Ltd.. Active years: 2020-2021.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2020-2021

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Bo Suel Kim: Innovator in Ginseng Saponin Research

Introduction

Bo Suel Kim is a notable inventor based in Busan, South Korea. He has made significant contributions to the field of ginseng saponin research, holding a total of 2 patents. His work focuses on the health benefits of ginseng saponins, particularly in cellular health and blood composition.

Latest Patents

Kim's latest patents revolve around the composition containing saponins as an active ingredient. These patents disclose the uses of ginseng saponin, which contains at least 90% of compounds K, Rd, F2, and Rg3. The main effects of these compounds include extending the lifespan of cells, promoting cell differentiation, increasing the number of red blood cells, and reducing triglycerides. The process involves extracting, heat-treating, and enzyme-converting ginseng saponin to prepare active saponins Rd, F2, and Rg3, including compound K.

Career Highlights

Bo Suel Kim is associated with Korean Drug Co., Ltd., where he continues to innovate in the field of pharmacology. His research has the potential to impact health and wellness significantly, particularly in the areas of aging and blood health.

Collaborations

Kim has collaborated with notable colleagues, including Choel-Min Kim and Heyong-Soo Kim. Their combined expertise enhances the research and development efforts at their company.

Conclusion

Bo Suel Kim's contributions to ginseng saponin research highlight his role as an innovator in the field. His patents reflect a commitment to advancing health solutions through scientific discovery.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…